NEW YORK, Dec. 22, 2017 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on FOLD, RDUS, SAGE, and PULM which can be accessed for free by signing up to www.wallstequities.com/registration. On Thursday, December 21, 2017, US markets saw broad based gains with seven out of nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,965.36, up 0.06%; the Dow Jones Industrial Average edged 0.23% higher, to finish at 24,782.29; and the S&P 500 closed at 2,684.57, up 0.20%. This Friday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: Amicus Therapeutics Inc. (NASDAQ: FOLD), Radius Health Inc. (NASDAQ: RDUS), Sage Therapeutics Inc. (NASDAQ: SAGE), and Pulmatrix Inc. (NASDAQ: PULM). All you have to do is sign up today for this free limited time offer, click the link below.
www.wallstequities.com/registration
Amicus Therapeutics
On Thursday, shares in Cranbury, New Jersey headquartered Amicus Therapeutics Inc. recorded a trading volume of 1.35 million shares. The stock ended the session 1.63% higher at $13.72. The Company's shares have gained 193.79% in the past twelve months and 176.06% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.84% and 22.34%, respectively. Moreover, shares of Amicus Therapeutics, which engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases, have a Relative Strength Index (RSI) of 58.82. Get the full research report on FOLD for free by clicking below at:
www.wallstequities.com/registration/?symbol=FOLD
Radius Health
Waltham, Massachusetts headquartered Radius Health Inc.'s stock closed the day 1.79% higher at $30.14 with a total trading volume of 482,305 shares. The Company's shares have advanced 11.46% in the past month. The stock is trading below its 50-day moving average by 0.85%. Additionally, shares of Radius Health, which develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the US, have an RSI of 52.06.
On December 06th, 2017, research firm Citigroup initiated a 'Neutral' rating on the Company's stock, with a target price of $30 per share. Free research on RDUS can be accessed at:
www.wallstequities.com/registration/?symbol=RDUS
Sage Therapeutics
Shares in Cambridge, Massachusetts headquartered Sage Therapeutics Inc. recorded a trading volume of 833,783 shares. The stock ended yesterday's trading session 4.92% lower at $155.40. The Company's shares have advanced 72.78% in the past month, 147.06% over the previous three months, 232.26% in the past twelve months, and 204.35% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 65.71% and 97.06%, respectively. Furthermore, shares of Sage Therapeutics, which develops and commercializes novel medicines to treat central nervous system disorders, have an RSI of 68.91.
On December 08th, 2017, research firm Needham reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $100 a share to $193 a share. Sign up today for the free research report on SAGE at:
www.wallstequities.com/registration/?symbol=SAGE
Pulmatrix
Lexington, Massachusetts headquartered Pulmatrix Inc.'s stock finished Thursday's session 1.35% lower at $1.46 with a total trading volume of 275,823 shares, which was above their three months average volume of 258.16 thousand shares. The Company's shares have advanced 147.46% in the past twelve months and 147.46% since the start of this year. The stock is trading below its 50-day moving average by 12.15%. Additionally, shares of Pulmatrix, which engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, have an RSI of 36.80. Wall St. Equities' research coverage also includes the downloadable free report on PULM at:
www.wallstequities.com/registration/?symbol=PULM
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Advertisement
www.wallstequities.com/registration
Amicus Therapeutics
On Thursday, shares in Cranbury, New Jersey headquartered Amicus Therapeutics Inc. recorded a trading volume of 1.35 million shares. The stock ended the session 1.63% higher at $13.72. The Company's shares have gained 193.79% in the past twelve months and 176.06% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.84% and 22.34%, respectively. Moreover, shares of Amicus Therapeutics, which engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases, have a Relative Strength Index (RSI) of 58.82. Get the full research report on FOLD for free by clicking below at:
Advertisement
www.wallstequities.com/registration/?symbol=FOLD
Radius Health
Waltham, Massachusetts headquartered Radius Health Inc.'s stock closed the day 1.79% higher at $30.14 with a total trading volume of 482,305 shares. The Company's shares have advanced 11.46% in the past month. The stock is trading below its 50-day moving average by 0.85%. Additionally, shares of Radius Health, which develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the US, have an RSI of 52.06.
On December 06th, 2017, research firm Citigroup initiated a 'Neutral' rating on the Company's stock, with a target price of $30 per share. Free research on RDUS can be accessed at:
www.wallstequities.com/registration/?symbol=RDUS
Sage Therapeutics
Shares in Cambridge, Massachusetts headquartered Sage Therapeutics Inc. recorded a trading volume of 833,783 shares. The stock ended yesterday's trading session 4.92% lower at $155.40. The Company's shares have advanced 72.78% in the past month, 147.06% over the previous three months, 232.26% in the past twelve months, and 204.35% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 65.71% and 97.06%, respectively. Furthermore, shares of Sage Therapeutics, which develops and commercializes novel medicines to treat central nervous system disorders, have an RSI of 68.91.
On December 08th, 2017, research firm Needham reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $100 a share to $193 a share. Sign up today for the free research report on SAGE at:
www.wallstequities.com/registration/?symbol=SAGE
Pulmatrix
Lexington, Massachusetts headquartered Pulmatrix Inc.'s stock finished Thursday's session 1.35% lower at $1.46 with a total trading volume of 275,823 shares, which was above their three months average volume of 258.16 thousand shares. The Company's shares have advanced 147.46% in the past twelve months and 147.46% since the start of this year. The stock is trading below its 50-day moving average by 12.15%. Additionally, shares of Pulmatrix, which engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, have an RSI of 36.80. Wall St. Equities' research coverage also includes the downloadable free report on PULM at:
www.wallstequities.com/registration/?symbol=PULM
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-biotech-equities----amicus-therapeutics-radius-health-sage-therapeutics-and-pulmatrix-300574913.html
SOURCE Wall St. Equities
